Released Aug 7, 2025, after the close
10-Q filed Aug 7, 2025, 38 days after period end · 0000950170-25-105219
Q2 2025 · 10-Q
Revenue$63.75M$63.75M +148.0% vs Q2 2024+266.4% vs Q1 2025
Net Income-$11.50M-$11.50M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$1.35-$1.35 N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$3,345,000N/M
Operating Cash Flowderived-$44,724,000N/M
Margins · derived
Operating margin-5.2%+184.1 pt vs Q2 2024
Net margin-18.0%+168.8 pt vs Q2 2024
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $63.75M | $25.71M | $10.41M | $28.10M |
| Net Income | -$11.50M | -$48.02M | -$38.52M | -$26.01M |
| EPS Diluted | -$1.35 | -$0.59 | -$0.64 | -$0.55 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR